Lanthanum carbonate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lanthanum carbonate and what is the scope of patent protection?
Lanthanum carbonate
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa, Barr, Invagen Pharms, and Natco Pharma Ltd, and is included in five NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Lanthanum carbonate has ninety-one patent family members in thirty-one countries.
There are nine drug master file entries for lanthanum carbonate. Six suppliers are listed for this compound.
Summary for lanthanum carbonate
International Patents: | 91 |
US Patents: | 4 |
Tradenames: | 2 |
Applicants: | 4 |
NDAs: | 5 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Clinical Trials: | 43 |
Patent Applications: | 1,525 |
Drug Prices: | Drug price trends for lanthanum carbonate |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lanthanum carbonate |
What excipients (inactive ingredients) are in lanthanum carbonate? | lanthanum carbonate excipients list |
DailyMed Link: | lanthanum carbonate at DailyMed |
Recent Clinical Trials for lanthanum carbonate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical Universtity of Lodz | Phase 4 |
Medical University of Lodz | Phase 4 |
Universitair Ziekenhuis Brussel | Phase 3 |
Pharmacology for lanthanum carbonate
Drug Class | Phosphate Binder |
Mechanism of Action | Phosphate Chelating Activity |
Anatomical Therapeutic Chemical (ATC) Classes for lanthanum carbonate
Paragraph IV (Patent) Challenges for LANTHANUM CARBONATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FOSRENOL | Oral Powder | lanthanum carbonate | 750 mg and 1000 mg | 204734 | 1 | 2015-11-25 |
FOSRENOL | Chewable Tablet | lanthanum carbonate | 500 mg, 750 mg and 1000 mg | 021468 | 3 | 2008-10-27 |
US Patents and Regulatory Information for lanthanum carbonate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Invagen Pharms | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 206868-002 | Jan 24, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-004 | Nov 23, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Barr | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090977-002 | Jan 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Natco Pharma Ltd | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090978-001 | Aug 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | POWDER;ORAL | 204734-002 | Sep 24, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-001 | Oct 26, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-003 | Nov 23, 2005 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lanthanum carbonate
International Patents for lanthanum carbonate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E029382 | ⤷ Sign Up | |
Cyprus | 1117082 | ⤷ Sign Up | |
European Patent Office | 2645995 | CAPSULE ET FORMULATIONS DE POUDRE CONTENANT DES COMPOSÉS DE LANTHANE (CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS) | ⤷ Sign Up |
Austria | 460169 | ⤷ Sign Up | |
Spain | 2478258 | ⤷ Sign Up | |
Portugal | 2172205 | ⤷ Sign Up | |
China | 103237543 | Capsule and powder formulations containing lanthanum compounds | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.